Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Quantum Pharma

- PMLiVE

Clinigen launches ‘What is Possible?’ campaign on Rare Disease Day to accelerate access to medicines

There are over 7,000 rare diseases impacting more than 300 million people globally

- PMLiVE

Clinigen’s NaviGATE programme reveals knowledge gaps in rare disease community

There are over 7,000 rare diseases that impact more than 300 million people globally

- PMLiVE

Clinigen launches educational programme for rare disease patients and organisations

The NaviGATE programme will aim to empower patients and provide navigational support

- PMLiVE

Quantum Pharma confirms Clinigen takeover bid

Clinigen has until September 13 to make a formal offer

- PMLiVE

Managed Access Programmes: a powerful source of real-world insight

MAPs represent a unique opportunity to gather evidence from a cohort of patients receiving the same treatment, across multiple countries prospectively before launch

- PMLiVE

Quantum Pharma promotes Chris Rigg to chief financial officer

He succeeds Martin Such in the role

- PMLiVE

Clinigen acquires Idis for £225m

Acquisition makes them the global leader in unlicensed medicines

The logistics of orphan drugs

Managing a rare disease global access programme, the goal is to minimise risk and get the drug to the patient on time

Orphan drugs: the early access regulatory environment

Despite considerable variation to the rules for unlicensed orphan drugs, there are some clear first steps for a global access programme

- PMLiVE

Eisai lines-up Fycompa access programme for Germany

But sales suspension for epilepsy drug will continue

BTG extends orphan drug distribution partnership with Clinigen

Deal covers treatment for overexposure to chemotherapy

Enabling access for patients with rare diseases

When it comes to meeting patient needs, the well-known counsel to ‘think globally, act locally’ rings true

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links